Competitor Analysis: Complement C5 Inhibitors & C5 Receptor Antagonists

Competitor Analysis: Complement C5 Inhibitors & C5 Receptor Antagonists

This Competitive Intelligence report about Complement C5 Inhibitors & C5 Receptor Antagonists provides a competitor evaluation in the field of mainly recombinant antibodies, but also proteins, peptides, RNA and small molecules acting as inibitors of complement C5 or antagonists of the C5 receptor as of July 2023.

With annual sales of more than US$ 5.7 bln in 2022, first and second generation C5 inhibitor antibodies Soliris and Ultomiris from AstraZeneca (acquired Alexion Pharmaceuticals) have set the stage for next generation biosuperiors as well as biosimilars of a commercially successful and clinically effective treatment of complement C5 mediated diseases. New treatment modalities in development aim at improving the mode and frequency of administration as well as the scope of indications. Players in the field not only include small and medium biotech, but also Big Pharmas.

This product consists of a competitor description in a tabular format provided as a pdf document and an one-month online access to La Merie Publishing’s database for this product (report code: LMCA0012) (prerequisite: access to internet). Both deliverables (pdf and database credentials) are sent by e-mail within one day, usually within one hour.

The pdf report includes a compilation of currently active projects in research and development of inhibitors of complement C5 or antagonists of the C5a receptor. In addition, the pdf report lists company-specific R&D pipelines of C5 inhibitors & C5R antagonists. Competitor projects are listed in a tabular format providing information on:

• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.

About Competitor Analysis reports:
Competitor Analysis reports deliver NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced. The LMCA0012 report database provides access to the history of each project with links to the source of information (press release, homepage, abstracts, presentations, annual reports etc). Furthermore, the database allows export of data into a Word or Excel document.